Ensol Biosciences Inc. (XKON:140610)

Market Cap	160.93B -58.5%
Revenue (ttm)	537.46M +208.9%
Net Income	-5.40B
EPS	-644.00
Shares Out	13.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,684
Open	12,490
Previous Close	12,220
Day's Range	11,700 - 12,490
52-Week Range	10,350 - 31,750
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Ensol Biosciences

Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 140610

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 21, 2026

Data Sources Report a data error